Core Insights - The China International Import Expo (CIIE) serves as a significant platform for international trade cooperation and mutual benefits, showcasing China's market potential to the world [1] - Amway (China) has launched a new multivitamin powder product, addressing nutritional gaps in the Chinese diet, marking it as the first "blue hat" multivitamin product in the market [1] - Amway has been operating in China for 30 years and has consistently ranked as the largest market for the company globally, viewing investment in China as a long-term strategy for future growth [1] Investment Plans - Amway has initiated a five-year investment plan from 2023 to 2027, amounting to 2.1 billion yuan, covering the entire operational chain in China [2] - The investment includes 700 million yuan for upgrading the Guangzhou production base, 400 million yuan for enhancing digital infrastructure, and 500 million yuan for improving over 100 experience stores nationwide [2] - An additional 500 million yuan is allocated for research and development, focusing on organic farming, anti-aging plant research, and space breeding projects [2] R&D and Innovation - Amway is building a local research and development system for traditional Chinese medicine, collaborating with various partners to innovate and modernize agricultural practices [2] - The company has partnered with China's space program for large-scale space breeding of traditional Chinese herbs and is working with universities and research institutions to develop new plant varieties [2] - Amway's R&D efforts not only support local product development but also facilitate the export of Chinese herbal products to global markets [2] Strategic Positioning - Amway aims to strengthen its supply chain and innovation capabilities in China, reinforcing the country's role as a strategic growth engine and supply chain hub for the company [2]